Perspective Therapeutics: FDA grants fast track for PSV359

What happened

• On Oct 8, 2026, Perspective Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors. The press release is filed as Exhibit 99.1 and is incorporated by reference into the 8-K.

Key details

• Event reported under Item 8.01, Other events.
• Drug: PSV359.
• Patient population: adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors.
• Press release dated Oct 8, 2026 and signed by Johan (Thijs) Spoor, Chief executive officer.

Why it may matter

• The filing reports Item 8.01, which covers other events and, in this case, the company-issued press release announcing the FDA Fast Track Designation for PSV359. The filing does not show why the insider traded or why the company acted.